Aurobindo Pharma Reports Strong Sales Growth Amid Rising Interest Expenses in March 2025 Results
Aurobindo Pharma has announced its financial results for the quarter ending March 2025, showcasing significant growth in net sales and operating profit, both reaching their highest levels in five quarters. However, the company also faced increased interest expenses, indicating challenges related to rising borrowings.
Aurobindo Pharma has recently reported its financial results for the quarter ending March 2025, revealing notable developments in its performance metrics. The company achieved net sales of Rs 8,382.12 crore, marking the highest figure recorded in the last five quarters. This positive trend in sales indicates a robust near-term outlook for the company's revenue generation.Additionally, Aurobindo Pharma reported an operating profit (PBDIT) of Rs 1,791.92 crore, also the highest in the past five quarters. This reflects a favorable trend in operational efficiency and profitability for the company during this period.
However, the financial results also highlight some challenges. The interest expense for the nine-month period reached Rs 346.20 crore, reflecting a growth of 25.43% compared to the preceding nine months. This increase in interest costs suggests a rise in borrowings, which may impact the company's financial flexibility.
Overall, Aurobindo Pharma has experienced evaluation changes in its financial score, moving from -8 to 0 over the last three months, indicating a shift in assessment based on the latest financial data.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
